[go: up one dir, main page]

BRPI0417509A - molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira - Google Patents

molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira

Info

Publication number
BRPI0417509A
BRPI0417509A BRPI0417509-3A BRPI0417509A BRPI0417509A BR PI0417509 A BRPI0417509 A BR PI0417509A BR PI0417509 A BRPI0417509 A BR PI0417509A BR PI0417509 A BRPI0417509 A BR PI0417509A
Authority
BR
Brazil
Prior art keywords
nucleic acid
hbc
recombinant
chimeric
particles
Prior art date
Application number
BRPI0417509-3A
Other languages
English (en)
Inventor
Ashley Birkett
Walter Fiers
Original Assignee
Apovia Inc
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/732,862 external-priority patent/US20040146524A1/en
Application filed by Apovia Inc, Vlaams Interuniv Inst Biotech filed Critical Apovia Inc
Publication of BRPI0417509A publication Critical patent/BRPI0417509A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

MOLéCULA DE PROTEìNA QUIMéRICA DE NúCLEO DE VìRUS DA HEPATITE B (HBC) RECOMBINANTE, PARTìCULAS, VACINA OU INóCULO, áCIDO NUCLEICO, MOLéCULA DE áCIDO NUCLEICO RECOMBINANTE, E, CéLULA HOSPEDEIRA Revela-se uma proteína de nucleocapsídeo do vírus da hepatite B (HBc) truncada carbóxi-terminal, quimérica, que contém um imunógeno para induzir a produção de anticorpos para a proteína M2 da influenza. Uma seqüência de influenza imunogênica, em de duas a quatro cópias, é expressa, de preferência, no N-terminal ou próximo da mesma, ou na seqüência de alça imunogênica da HBc. A quimera de HBc contém, de preferência, um epitopo de células T específico para influenza e é manipulado, de preferência para maior estabilidade de partículas auto-montadas, e também para maior rendimento dessas partículas quiméricas. Revela-se também métodos para preparar e usar as quimeras.
BRPI0417509-3A 2003-12-10 2004-12-09 molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira BRPI0417509A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/732,862 US20040146524A1 (en) 2002-02-21 2003-12-10 Stabilized immunogenic HBc chimer particles
US10/787,734 US7361352B2 (en) 2001-08-15 2004-02-26 Influenza immunogen and vaccine
PCT/US2004/041879 WO2005055957A2 (en) 2003-12-10 2004-12-09 Influenza immunogen and vaccine

Publications (1)

Publication Number Publication Date
BRPI0417509A true BRPI0417509A (pt) 2007-05-08

Family

ID=34681746

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417509-3A BRPI0417509A (pt) 2003-12-10 2004-12-09 molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira

Country Status (11)

Country Link
US (2) US7361352B2 (pt)
EP (2) EP1708748A4 (pt)
JP (1) JP2007513634A (pt)
KR (1) KR101209484B1 (pt)
CN (1) CN1913920B (pt)
AU (1) AU2004296886B2 (pt)
BR (1) BRPI0417509A (pt)
CA (1) CA2549104A1 (pt)
IL (1) IL200341A (pt)
NO (1) NO20063157L (pt)
WO (1) WO2005055957A2 (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
EP1572234B1 (en) * 2002-12-10 2012-02-22 Sanofi Pasteur Biologics Co. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
SI1861120T1 (sl) 2005-03-23 2016-09-30 Glaxosmithkline Biologicals S.A. Uporaba virusa influence in adjuvansa emulzije olja v vodi za induciranje odziva CD4 T celic in/ali izboljšanega odziva B spominskih celic
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
DK1951296T4 (da) 2005-11-01 2014-09-01 Novartis Vaccines & Diagnostic Celleafledte viral vacciner med lave niveauer af restcelle-DNA
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE202006021242U1 (de) * 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
PT1968630T (pt) * 2005-12-29 2018-04-12 Boehringer Ingelheim Vetmedica Inc Composições imunogénicas de pcv2 multivalentes
CN104383526B (zh) * 2005-12-29 2018-09-18 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2免疫原性组合物用于减轻猪临床症状的用途
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
WO2007127290A2 (en) * 2006-04-24 2007-11-08 Protelix, Inc. Method for producing viral vaccine and therapeutic peptide antigens
JP2009543554A (ja) 2006-07-14 2009-12-10 サノフィ パスツール バイオロジクス カンパニー ベクターウイルスタンパク質への外来免疫決定基の直接トランスポゾン媒介挿入による組換え型ウイルスワクチンの構築
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
BRPI0716536A2 (pt) * 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
AU2007318206A1 (en) 2006-09-29 2008-05-15 Sanofi Pasteur Biologics Co. Novel neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications
US20100239605A1 (en) * 2006-09-29 2010-09-23 Sanofi Pasteur Biologics Co. Recombinant Rhinovirus Vectors
TWI417113B (zh) 2006-11-07 2013-12-01 Acambis Inc 以凍乾法穩定疫苗
EP2069503B1 (en) * 2006-11-15 2016-01-06 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) * 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
US8865183B2 (en) * 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP2606903B1 (en) 2007-01-10 2016-09-14 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
EP2117588A4 (en) * 2007-02-09 2011-05-04 Sanofi Pasteur Biologics Co VIRAL VECTORS AND METHODS OF USE
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CA2682047A1 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for increasing immunogenicity of glycoprotein vaccines
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
KR20100075843A (ko) * 2007-08-21 2010-07-05 다이나박스 테크놀로지 코퍼레이션 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
WO2009079564A2 (en) * 2007-12-17 2009-06-25 Emory University Immunogenic compositions and methods of use thereof
KR20100103535A (ko) * 2007-12-31 2010-09-27 베링거잉겔하임베트메디카인코퍼레이티드 외래 아미노산 삽입물을 갖는 ｐｃｖ２ ｏｒｆ２ 바이러스 유사 입자
CA2712006A1 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
EP2240199A4 (en) * 2008-02-09 2012-10-03 Sanofi Pasteur Biologics Llc INFLUENZA VACCINES
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
CA2743306A1 (en) 2008-11-12 2010-05-20 Theraclone Sciences, Inc. Human m2e peptide immunogens
KR101779616B1 (ko) * 2008-12-10 2017-09-18 퍼듀 리서치 파운데이션 키나아제의 세포-침투성 펩티드-기초된 저해물질
WO2010086743A2 (en) 2009-02-02 2010-08-05 Chrontech Pharma Ab Compositions and methods that enhance an immune response
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EA034702B1 (ru) * 2011-04-26 2020-03-10 Молекулар Экспресс, Инк. Липосомные композиции
CN103083656A (zh) * 2011-10-27 2013-05-08 苏州科贝生物技术有限公司 甲型流感病毒保守肽M2e与病毒样颗粒的缀合物及应用
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP3789002A1 (en) * 2012-09-05 2021-03-10 Stryker Corporation Patient support
WO2014074509A1 (en) * 2012-11-07 2014-05-15 Vacplanta Limted Production of an immunogen using a plant virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
MX373884B (es) 2013-10-02 2020-03-26 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
JP2021533134A (ja) 2018-08-02 2021-12-02 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム チェックポイント阻害抗体と相乗効果を示し、疾患を排除するｔｌｒ１／２アゴニストジプロボッシムのアジュバント効果
US20220356538A1 (en) * 2019-09-24 2022-11-10 The Penn State Research Foundation Hepatitis b virus mutants with increased covalently closed circular dna
CN115916343B (zh) 2020-03-26 2024-07-02 普罗维克图斯药品技术公司 卤代呫吨在肿瘤学和病毒学中的新用途
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
CA3212672A1 (en) * 2021-03-04 2022-09-09 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4976958A (en) * 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL91525A0 (en) 1988-09-06 1990-04-29 Univ Washington Transgenic plants,pharmaceutical compositions containing the same and methods for the preparation thereof
US5023179A (en) 1988-11-14 1991-06-11 Eric Lam Promoter enhancer element for gene expression in plant roots
US5110732A (en) 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
JP3782442B2 (ja) 1990-03-02 2006-06-07 ビーピー・コーポレーション・ノース・アメリカ・インコーポレーテッド 遺伝子操作した宿主におけるカロテノイドの生合成
US5618988A (en) 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
US5057588A (en) 1990-03-09 1991-10-15 Hoechst Celanese Corp. Vinylidene cyanide alternating copolymers
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
US5297441A (en) 1992-08-14 1994-03-29 The Boeing Company Apparatus for supporting a test specimen for compression testing
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JP3701761B2 (ja) * 1997-01-08 2005-10-05 本田技研工業株式会社 車両用シート
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ATE286399T1 (de) 1997-05-20 2005-01-15 Galenica Pharmaceuticals Inc Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
WO1999007839A2 (en) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6024961A (en) 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
WO1999030737A1 (en) 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
EP1054689B1 (en) 1998-02-12 2003-09-10 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US5990085A (en) * 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
EP1075276B1 (en) 1998-05-07 2007-10-17 Corixa Corporation Adjuvant composition and methods for its use
PL348766A1 (en) 1998-12-04 2002-06-03 Biogen Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
EP1218514B1 (en) 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
WO2001041759A1 (en) 1999-12-10 2001-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulation of oocyte activation
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US20030198645A1 (en) * 2002-02-21 2003-10-23 Mark Page Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis

Also Published As

Publication number Publication date
CN1913920B (zh) 2013-03-27
EP2425848A3 (en) 2012-06-20
CA2549104A1 (en) 2005-06-23
EP2425848A2 (en) 2012-03-07
WO2005055957A2 (en) 2005-06-23
US8017127B2 (en) 2011-09-13
EP1708748A4 (en) 2008-03-19
KR20070008535A (ko) 2007-01-17
NO20063157L (no) 2006-09-11
US20060115489A1 (en) 2006-06-01
AU2004296886B2 (en) 2008-10-02
CN1913920A (zh) 2007-02-14
US7361352B2 (en) 2008-04-22
EP1708748A2 (en) 2006-10-11
JP2007513634A (ja) 2007-05-31
AU2004296886A1 (en) 2005-06-23
WO2005055957A3 (en) 2005-11-03
KR101209484B1 (ko) 2012-12-07
US20070036826A1 (en) 2007-02-15
IL200341A (en) 2013-01-31

Similar Documents

Publication Publication Date Title
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
Lua et al. Bioengineering virus‐like particles as vaccines
RU2011128371A (ru) Модифицированные f протеины sv и способы их применения
Arora et al. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
RU2351651C2 (ru) Выделенный рекомбинантный вирус гриппа и способы его получения
RU2014101401A (ru) Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
Babin et al. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP
BRPI0416393A (pt) molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado
RU2014142785A (ru) Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
JP2009268467A5 (pt)
BRPI0614761A2 (pt) proteìnas de fusão de albumina
CA2413546A1 (en) Modification of hepatitis b core antigen
EA201170217A1 (ru) Гибридные полипептидные антигены респираторно-синцитиального вируса
AR045804A1 (es) Expresion optimizada de l1 del vph45 en levaduras
MXPA05008677A (es) Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica.
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
RU2014135703A (ru) Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2, h2n2 и b
JP2010532656A5 (pt)
CN114364692A (zh) 嵌合的乳头瘤病毒l1蛋白
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
Akhras et al. Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response
WO2002081709A3 (en) Modified hpv e6 and e7 genes and proteins useful for vaccination
JP2012516140A5 (pt)
CA2509484A1 (en) Stabilized immunogenic hbc chimer particles

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.